Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

Scientists created a serum containing extracts from a tropical plant and specialized proteins that support hair follicle ...

Apple's fiercely loyal customer base gives it a built-in market for any new devices it might launch in the future. MercadoLibre is positioned to grow rapidly in the Latin America e-commerce and ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

It's a good idea to go against the current market sentiment on this one. Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...

Physics and Python stuff. Most of the videos here are either adapted from class lectures or solving physics problems. I really like to use numerical calculations without all the fancy programming ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.

Days after Inc42 reported Kiwi securing INR 208.5 Cr (around $24 Mn) in its Series B funding round led by Vertex Ventures, the startup has now confirmed the development. In a statement, the startup ...

Vertex Pharmaceuticals (VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically had a strong R&D pipeline and has consistently been a winner, but the ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...